Ofatumumab Plus Bendamustine in Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
British Journal of Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase 3, Randomized Study of Ofatumumab Combined With Bendamustine in Rituximab-Refractory iNHL (COMPLEMENT A + B Study)
Br. J. Haematol 2021 May 10;[EPub Ahead of Print], MJ Rummel, A Janssens, D MacDonald, MM Keating, JM Zaucha, J Davis, J Lasher, C Babanrao Pisal, M Izquierdo, JW FriedbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.